newsfilter
← Latest News
Business Wire·

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

EQ

Financing led by ADAR1 Capital Management and Janus Henderson Investors $30 million up front with the potential to receive an additional $20 million at clinical study initiation Phase 1 clinical study initiation